The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
|Videos|February 19, 2015
Toxicities Associated With CAR-Modified T Cell Therapy
Author(s)Jae Park, MD
Jae Park, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses toxicities associated with CAR-modified T cell therapy.
Advertisement
Clinical Pearls
Jae Park, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses toxicities associated with CAR-modified T cell therapy.
- There are unique toxicities associated with CAR-modified T cell therapy, such as cytokine release syndrome.
- Cytokine release syndrome can cause a patient to experience fever, low blood pressure, and breathing problems.
- There are now ways for a physician to predict the occurrence and severity of cytokine release syndrome.
- IL-6 receptor inhibitors or steroids can effectively manage cytokine release syndrome.
Advertisement
Related to this article
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
FYB206 is being reviewed as a pembrolizumab biosimilar after meeting pharmacokinetic equivalence; no additional efficacy trial is required.
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies, yet gaps persist, and research funding uncertainty threatens future gains.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Real-World Data for Darolutamide vs Abiraterone Triplet Therapy in mHSPC
4
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
5